As the Senior Vice President of Program and Portfolio Management at Latigo Bio, Julia leads the strategic planning and operational execution of the company’s portfolio of non-opioid medicines for acute and chronic pain.  With more than 15 years of experience in public and private biopharmaceutical companies, Julia brings deep expertise in advancing complex, cross-functional therapeutic programs from discovery to commercialization.

Before joining Latigo, Julia held leadership positions in corporate strategy, program management, and business development at Novartis, BridgeBio, Verve, and Precision Biosciences.  In these roles, she managed strategic planning for the Novartis flu franchise and BridgeBio gene therapy pipeline, oversaw pandemic readiness initiatives in collaboration with other companies and government entities, supported partnerships worth over $2.5 billion with Gilead, Lilly, Shire, and Vertex, and facilitated the development and manufacturing of numerous vaccines and biologics.

Julia holds an MBA and bachelor’s degree in biomedical engineering from Duke University.